To the full analysis
Redcare Pharmacy stock: growth
RDC.DERedcare Pharmacy reported $3.26B in revenue for fiscal 2025, up 24.1% on the prior year, up 24.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
39.3%
per year from 2013 to 2025, per share 30.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 24.9% | 37.1% | 39.3% |
| Revenue per share | 16.8% | 26.6% | 30.3% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $61.27M | −$3.14M | −$9.73M |
| 2014 | $93.82M | −$5.58M | −$6.63M |
| 2015 | $139.15M | −$11.69M | −$14.22M |
| 2016 | $196.57M | −$20.44M | −$23.37M |
| 2017 | $314.69M | −$23.67M | −$36.41M |
| 2018 | $598.05M | −$37.24M | −$39.22M |
| 2019 | $776.79M | −$40.19M | −$49.98M |
| 2020 | $1.07B | −$18.58M | −$39.37M |
| 2021 | $1.17B | −$82.2M | −$34.93M |
| 2022 | $1.33B | −$86.04M | −$91.57M |
| 2023 | $1.99B | −$13.34M | $25.75M |
| 2024 | $2.63B | −$50.38M | $14.83M |
| 2025 | $3.26B | −$41.78M | −$62.39M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2017)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.